

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

### **宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

## **I. POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2025**

### **II. APPOINTMENT OF DIRECTOR**

The board of directors (the “**Board**”) of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”) is pleased to announce the poll results of the annual general meeting (the “**AGM**”) held at Unit 15, 1000 Zhangheng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai, PRC on May 28, 2025 at 9:30 a.m. The AGM was convened by the Board in accordance with the Company Law of the PRC and the Articles of Association, and was chaired by Dr. Tian Wenzhi, the chairman of the Board, the chief executive officer, the chief scientific officer and an executive Director of the Company.

References are made to the notice of the AGM and the circular of the AGM of the Company both dated April 30, 2025 (the “**Circular**”). Unless otherwise defined, terms used in this announcement shall have the same meanings as those defined in the Circular.

## **I. POLL RESULTS OF THE ANNUAL GENERAL MEETING**

### **Attendance of the AGM**

Shareholders holding an aggregate of 231,375,213 Shares (comprising 220,344,823 H Shares and 11,030,390 Unlisted Shares), representing approximately 56.81% of the total issued Shares, attended the AGM either in person or by proxy.

## Poll Results of Resolutions Proposed at the AGM

All proposed resolutions as set out in the notice of the AGM dated April 30, 2025 were taken by poll. The poll results are as follows:

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes (%)	
		FOR	AGAINST
1.	To consider and approve the work report of the Board of Directors of the Company (the “ <b>Board</b> ”) for the year 2024.	231,375,213 (100%)	0 (0%)
2.	To consider and approve the work report of the supervisory committee of the Company (the “ <b>Supervisory Committee</b> ”) for the year 2024.	231,375,213 (100%)	0 (0%)
3.	To consider and approve the annual report of the Company for the year 2024.	231,375,213 (100%)	0 (0%)
4.	To consider and approve the final financial report of the Company for the year 2024 and the financial budget report of the Company for the year 2025.	230,923,613 (99.80%)	451,600 (0.20%)
5.	To consider and approve the 2024 Profit Distribution Plan.	231,375,213 (100%)	0 (0%)
6a.	To consider and approve the appointment of Mr. Zhang Ruliang as an executive Director of the Company with the term of office, upon approval at the Annual General Meeting and ending upon the expiry of the term of appointment of the second session of the Board.	229,545,040 (99.21%)	1,830,173 (0.79%)
6b.	To consider and approve the appointment of Ms. Fu Dawei as a non-executive Director of the Company with the term of office, upon approval at the Annual General Meeting and ending upon the expiry of the term of appointment of the second session of the Board.	229,545,040 (99.21%)	1,830,173 (0.79%)
6c.	To consider and approve the re-election of Dr. Tian Wenzhi as executive Director of the second session of the Board.	229,545,040 (99.21%)	1,830,173 (0.79%)

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes (%)	
		FOR	AGAINST
6d.	To consider and approve the re-election of Mr. Li Song as executive Director of the second session of the Board.	229,545,040 (99.21%)	1,830,173 (0.79%)
6e.	To consider and approve the re-election of Ms. Guan Mei as executive Director of the second session of the Board.	229,545,040 (99.21%)	1,830,173 (0.79%)
6f.	To consider and approve the re-election of Dr. Xu Cong as non-executive Director of the second session of the Board.	229,545,040 (99.21%)	1,830,173 (0.79%)
6g.	To consider and approve the re-election of Dr. Zhenping Zhu as independent non-executive Director of the second session of the Board.	231,375,213 (100%)	0 (0%)
6h.	To consider and approve the re-election of Dr. Kendall Arthur Smith as independent non-executive Director of the second session of the Board.	231,375,213 (100%)	0 (0%)
6i.	To consider and approve the re-election of Mr. Yeung Chi Tat as independent non-executive Director of the second session of the Board.	231,375,213 (100%)	0 (0%)
7.	To consider and approve the re-election of Ms. Tian Miao as a shareholder representative Supervisor of the second session of the Supervisory Committee.	229,545,040 (99.21%)	1,830,173 (0.79%)
8.	To consider and approve the re-appointment of Deloitte Touche Tohmatsu as the auditor of the Company for the year 2025 and to authorise the Board to determine its remuneration.	231,375,213 (100%)	0 (0%)
9.	To consider and approve the directors remuneration plan for the year 2025.	231,375,213 (100%)	0 (0%)
10.	To consider and approve the supervisors remuneration plan for the year 2025.	231,375,213 (100%)	0 (0%)
11.	To consider and approve the proposed change in use of proceeds.	231,375,213 (100%)	0 (0%)

As more than half of the votes were casted in favour of the resolutions numbered 1 to 11, all the above resolutions were duly passed as ordinary resolutions.

SPECIAL RESOLUTIONS		FOR	AGAINST
12.	To consider and approve granting of a general mandate to the Board to exercise the right to allot, issue and/or deal with new shares of the Company.	229,093,440 (99.01%)	2,281,773 (0.99%)
13.	To consider and approve the proposed grant of general mandate to the Board to repurchase H Shares.	231,375,213 (100%)	0 (0%)

As more than two-thirds of the votes were casted in favour of the resolutions numbered 12 to 13, the above resolutions were duly passed as a special resolution.

*Notes:*

- (a) As at the date of the AGM, the total number of issued Shares was 407,307,695 Shares (including 396,277,305 H Shares and 11,030,390 Unlisted Shares), which represented the total number of Shares entitling the Shareholders to attend and vote on the proposed resolutions at the AGM.
- (b) To the best knowledge, information and belief of the Company: (1) there were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”); (2) no shareholder of the Company was required under the Listing Rules to abstain from voting on the resolutions at the AGM; and (3) none of the shareholders of the Company has stated his/her/its intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.
- (c) The total number of issued Shares held by the Shareholders or their proxies who have attended the AGM and are entitled to vote is 231,375,213 Shares, representing approximately 56.81% of the total number of issued Shares as at the date of the AGM.
- (d) The Company’s H share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM. One Supervisor of the Company and two Shareholders’ representatives also participated in the vote-taking and the scrutiny of the poll results at the AGM.
- (e) All Directors of the Company attended the AGM in person or by electronic means.

## II. APPOINTMENT OF DIRECTOR

Upon approval by the Shareholders at the AGM, Mr. Zhang Ruliang (“**Mr. Zhang**”) was appointed as an executive Director and Ms. Fu Dawei (“**Ms. Fu**”) was appointed as a non-executive Director of the second session of the Board. The term of office of Mr. Zhang and Ms. Fu shall be commencing from May 28, 2025 until the expiration of the term of office of the second session of the Board. The biographical details of the aforesaid Directors have been set out in the announcement of the Company (the “**Announcement**”) dated September 30, 2024 and October 14, 2024, respectively, and Circular in accordance with Rule 13.51(2) of the Listing Rules. As of the date of this announcement, there is no change to such information.

By order of the Board  
**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
**Tian Wenzhi**  
*Chairman and Executive Director*

Shanghai, the PRC, May 28, 2025

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song Ms. Guan Mei and Mr. Zhang Ruliang as executive Directors; (ii) Dr. Xu Cong and Ms. Fu Dawei as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*